Sharma P, Allison JP. The way forward for immune checkpoint remedy. Science. 2015;348:56–61.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Major, adaptive, and purchased resistance to most cancers immunotherapy. Cell. 2017;168:707–23.
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Pointers for the analysis of immune remedy exercise in strong tumors: immune-related response standards. Clin Most cancers Res. 2009;15:7412–20.
Borcoman E, Nandikolla A, Lengthy G, Goel S, Le Tourneau C. patterns of response and development to immunotherapy. Am Soc Clin Oncol Educ Ebook. 2018;38:169–78.
Guillerey C, Huntington ND, Smyth MJ. Concentrating on pure killer cells in most cancers immunotherapy. Nat Immunol. 2016;17:1025–36.
Waldman AD, Fritz JM, Lenardo MJ. A information to most cancers immunotherapy: from T cell fundamental science to scientific apply. Nat Rev Immunol. 2020;20:651–68.
Jiang X, Dudzinski S, Beckermann KE, Younger Ok, McKinley E, JM O, Rathmell JC, Xu J, Gore JC. MRI of tumor T cell infiltration in response to checkpoint inhibitor remedy. J Immunother Most cancers. 2020. https://doi.org/10.1136/jitc-2019-000328.
LaSalle T, Austin EE, Rigney G, Wehrenberg-Klee E, Nesti S, Larimer B, Mahmood U. Granzyme B PET imaging of immune-mediated tumor killing as a device for understanding immunotherapy response. J Immunother Most cancers. 2020. https://doi.org/10.1136/jitc-2019-000291.
Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, Lantto J, Horak ID, Kragh M, Nielsen CH, Kjaer A. CD4(+) and CD8a(+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: research of Sym021 in syngeneic mouse most cancers fashions. Theranostics. 2019;9:8221–38.
Tavaré R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, Witte ON, Ribas A, Wu AM. An Efficient immuno-PET imaging technique to observe cd8-dependent responses to immunotherapy. Most cancers Res. 2016;76:73–82.
Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty Ok, Boland G, Mahmood U. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Most cancers Res. 2017;77:2318–27.
Gibson HM, McKnight BN, Malysa A, Dyson G, Wiesend WN, McCarthy CE, Reyes J, Wei WZ, Viola-Villegas NT. IFNγ PET imaging as a predictive device for monitoring response to tumor immunotherapy. Most cancers Res. 2018;78:5706–17.
Edwards KJ, Chang B, Babazada H, Lohith Ok, Park DH, Farwell MD, Sellmyer MA. Utilizing CD69 PET imaging to observe immunotherapy-induced immune activation. Most cancers Immunol Res. 2022;10(9):1084.
Zhao H, Wang C, Yang Y, Solar Y, Wei W, Wang C, Wan L, Zhu C, Li L, Huang G, Liu J. ImmunoPET imaging of human CD8(+) T cells with novel (68)Ga-labeled nanobody companion diagnostic brokers. J Nanobiotechnology. 2021;19:42.
DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82.
Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guerin M, Biton J, Ouakrim H, et al. Macrophages impede CD8 T cells from reaching tumor cells and restrict the efficacy of anti-PD-1 therapy. Proc Natl Acad Sci U S A. 2018;115:E4041–50.
Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, et al. Excessive-dimensional evaluation delineates myeloid and lymphoid compartment transforming throughout profitable immune-checkpoint most cancers remedy. Cell. 2018;175:1443.
Qu Y, Wen J, Thomas G, Yang W, Prior W, He W, Sundar P, Wang X, Potluri S, Salek-Ardakani S. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab therapy. Cell Rep. 2020;32: 108115.
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic most cancers fashions. Most cancers Res. 2014;74:5057–69.
Solar J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, Adebayo O, Bash H, Chen Y, Maksimos M, et al. Tumor-associated macrophages in a number of myeloma: advances in biology and remedy. J Immunother Most cancers. 2022;10(4):e003975.
Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Most cancers Cell. 2014;26:623–37.
Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208:1949–62.
Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, et al. Arginase I manufacturing within the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Most cancers Res. 2004;64:5839–49.
Gyori D, Lim EL, Grant FM, Spensberger D, Roychoudhuri R, Shuttleworth SJ, Okkenhaug Ok, Stephens LR, Hawkins PT. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Perception. 2018. https://doi.org/10.1172/jci.perception.120631.
Choi JY, Jeong JM, Yoo BC, Kim Ok, Kim Y, Yang BY, Lee YS, Lee DS, Chung JK, Lee MC. Improvement of 68Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. Nucl Med Biol. 2011;38:371–9.
Park JB, Suh M, Park JY, Park JK, Kim YI, Kim H, Cho YS, Kang H, Kim Ok, Choi JH, et al. Evaluation of irritation in pulmonary artery hypertension by (68)Ga-mannosylated human serum albumin. Am J Respir Crit Care Med. 2020;201:95–106.
Lee S-P, Im H-J, Kang S, Chung S-J, Cho YS, Kang H, Park HS, Hwang D-W, Park J-B, Paeng J-C, et al. Noninvasive Imaging of myocardial irritation in myocarditis utilizing (68)Ga-tagged mannosylated human serum albumin positron emission tomography. Theranostics. 2017;7:413–24.
Park JY, Tune MG, Kim WH, Kim KW, Lodhi NA, Choi JY, Kim YJ, Kim JY, Chung H, Oh C, et al. Versatile and finely tuned albumin nanoplatform based mostly on click on chemistry. Theranostics. 2019;9:3398–409.
Park CR, Jo JH, Tune MG, Park JY, Kim YH, Youn H, Paek SH, Chung JK, Jeong JM, Lee YS, Kang KW. Secreted protein acidic and wealthy in cysteine mediates lively focusing on of human serum albumin in U87MG xenograft mouse fashions. Theranostics. 2019;9:7447–57.
Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference vary for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med. 2013;54:677–82.
Aide N, De Pontdeville M, Lopci E. Evaluating response to immunotherapy with (18)F-FDG PET/CT: the place will we stand? Eur J Nucl Med Mol Imaging. 2020;47:1019–21.
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a goal for novel most cancers remedy. Most cancers Deal with Rev. 2018;63:40–7.
Home IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Most cancers Res. 2020;26:487–504.
Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. Low-dose irradiation applications macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates efficient T cell immunotherapy. Most cancers Cell. 2013;24:589–602.
Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 remedy. Nat Commun. 2019;10:2416.
Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, et al. Immuno-PET identifies the myeloid compartment as a key contributor to the result of the antitumor response underneath PD-1 blockade. Proc Natl Acad Sci USA. 2019;116:16971–80.
Theivanthiran B, Evans KS, DeVito NC, Plebanek M, Sturdivant M, Wachsmuth LP, Salama AK, Kang Y, Hsu D, Balko JM, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Make investments. 2020;130:2570–86.
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in most cancers prognosis and therapeutic efficacy. Nat Rev Most cancers. 2020;20:662–80.
Tavaré R, Danton M, Giurleo JT, Makonnen S, Hickey C, Arnold TC, Kelly MP, Fredriksson F, Bruestle Ok, Hermann A, et al. Immuno-PET monitoring of lymphocytes utilizing the CD8-specific antibody REGN5054. Most cancers Immunol Res. 2022. https://doi.org/10.1158/2326-6066.CIR-21-0405.
Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental tips. Immunity. 2014;41:14–20.
Mosser DM, Edwards JP. Exploring the total spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.
Li Y, Wu H, Ji B, Qian W, Xia S, Wang L, Xu Y, Chen J, Yang L, Mao H. Focused imaging of cd206 expressing tumor-associated M2-like macrophages utilizing mannose-conjugated antibiofouling magnetic iron oxide nanoparticles. ACS Appl Bio Mater. 2020;3:4335–47.
Zhou X, Liu Y, Hu M, Wang M, Liu X, Huang L. Relaxin gene supply modulates macrophages to resolve most cancers fibrosis and synergizes with immune checkpoint blockade remedy. Sci Adv. 2021;7(8):eabb596.
Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, Li D, Calvo R, Dashnyam M, Singh A, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020. https://doi.org/10.1126/scitranslmed.aax6337.
Arlauckas SP, Garren SB, Garris CS, Kohler RH, Oh J, Pittet MJ, Weissleder R. Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics. 2018;8:5842–54.
Huang Y-Ok, Wang M, Solar Y, Di Costanzo N, Mitchell C, Achuthan A, Hamilton JA, Busuttil RA, Boussioutas A. Macrophage spatial heterogeneity in gastric most cancers outlined by multiplex immunohistochemistry. Nat Commun. 2019;10:3928.
Sankar Ok, Ye JC, Li Z, Zheng L, Tune W, Hu-Lieskovan S. The position of biomarkers in personalised immunotherapy. Biomark Res. 2022;10:32.
Wang DR, Wu XL, Solar YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Sign Transduct Goal Ther. 2022;7:331.
